On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions. One of the concerns was how the price, which didn’t accompany the original company press statement, would be …
ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe Read More »
Dear HIV Community Writer, ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine. This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that …
GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication Read More »
This drug will compete against raltegravir (Merck) and elvitegravir (Gilead). It will be dosed once a day for treatment naive patients and twice a day for treatment experienced. Issued: Monday 02 April 2012, London, UK Press release issued by Shionogi-ViiV Healthcare LLC, a joint venture between ViiV Healthcare Ltd (a global specialist HIV company established …
FOR IMMEDIATE RELEASE: February 9, 2012 Contact: Nelson Vergel (NelsonVergel@yahoo.com) Activists Caution HIV+ Patients and their Physicians About Monotherapy in Upcoming Access Program New York, February 9, 2012—AIDS activists and physician advocates welcome the news that ViiV Healthcare will be providing expanded access of dolutegravir (DTG), a new investigational integrase inhibitor for HIV patients with …
By Nelson Vergel Powerusa.org Dr Joe Eron presented new dosing and efficacy phase 2b data on the new GSK integrase inhibitor dolutegravir (DTG, S/GSK1349572) using 50 mg twice a day in patients whose HIV virus has developed resistance to raltegravir (Isentress). Prior data presented in Vienna from a cohort (cohort 1) of patients who took …
Dolutegravir, Trii and new abacavir data- How it all ties together Read More »
Pipeline Problems by David Evans In the past month, two companies shelved their once-promising experimental HIV drugs, citing the challenging nature of bringing a profitable product to market. Has the overwhelming success of modern-day HIV drugs jeopardized the future of new HIV treatment options? Since Matt Sharp first learned that he was HIV positive in …
